Advertisement

Viral Liver Diseases

  • Satheesh Nair
  • Jihad O. Arteh
Chapter

Abstract

Hepatitis A, Hepatitis B, and Hepatitis C are the most common types of viral hepatitis. Other types include Hepatitis E and Hepatitis D. Hepatitis A virus (HAV) infection can produce a significant illness in adults with severity increasing with advancing age. Once acute HAV infection resolves, patients develop lifelong immunity. HAV does not cause chronic infection and treatment is supportive. Up to 1.4 million persons in the USA and 350 million worldwide are infected with HBV. The majority of adult patients with acute HBV spontaneously clear the infection. Five percent of patients, however, progress into chronic hepatitis B. The natural history of chronic HBV infection includes four phases: immune tolerance, immune clearance, inactive carrier state, and reactivation. Most chronic HBV encountered in older patients is in the form of “e antigen”-negative chronic HBV. Treatment of HBV is mainly indicated in the immune clearance and reactivation phase. Entecavir and tenofovir have the best profile in terms of safety, potency, and genetic barrier to resistance. Hepatitis C virus (HCV) is the leading indication for liver transplant in the USA and Europe. Most patients who get infected with HCV develop chronic HCV with 25–30% of them progressing to cirrhosis. Liver biopsy and genotype (types 1, 2, or 3) are important when deciding on treatment. Pegylated interferon alpha in combination with ribavirin and a protease inhibitor is the current available therapy for HCV. Several new directly acting agents are in clinical trials and will substantially increase the response rate in HCV.

Keywords

Sustained Virologic Response Pegylated Interferon Alpha 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Daniels D, Grytdal S, Wasley A. Surveillance for acute viral hepatitis—United States, 2007. Centers for Disease Control and Prevention (CDC). MMWR Surveill Summ. 2009;58(3):1–27.PubMedGoogle Scholar
  2. 2.
    Bell BP, Kruszon-Moran D, Shapiro CN, et al. Hepatitis A virus infection in the United States: serologic results from the Third National Health and Nutrition Examination Survey. Vaccine. 2005;23:5798–806.PubMedCrossRefGoogle Scholar
  3. 3.
    Forbes A, Williams R. Increasing age. An important adverse prognostic factor in hepatitis A virus infection. J R Coll Physicians Lond. 1988;22:237–9.PubMedGoogle Scholar
  4. 4.
    Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med. 1998;338:286.PubMedCrossRefGoogle Scholar
  5. 5.
    Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705.PubMedGoogle Scholar
  6. 6.
    Thabut D, Le Calvez S, Thibault V, et al. Hepatitis C in 6,865 patients 65 years or older: a severe and neglected curable disease? Am J Gastroenterol. 2006;101:1260–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349(9055):825–32.PubMedCrossRefGoogle Scholar
  8. 8.
    Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Charlotte rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol. 2001;34:730–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Eslam M, Khattab MA, Harrison SA. Insulin resistance and hepatitis C: an evolving story. Gut. 2011, Gut Online First, published on 19 Jan 2011 as  10.1136/gut.2010.
  10. 10.
    Patel K, Thompson A, Chuang W, et al. Insulin resistance is independently associated with significant hepatic fibrosis in Asian chronic hepatitis C genotype 2 or 3 patients. J Gastroenterol Hepatol. 2011;26(7):1182–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Conjeevaram HS, Wahed AS, Afdhal N, et al., Virahep-C Study Group. Changes in insulin sensitivity and body weight during and after PEG interferon and ribavirin therapy for hepatitis C. Gastroenterology. 2011;140:469–77.Google Scholar
  12. 12.
    Jacobson IM, Cacoub P, Dal Maso L, Harrison SA, Younossi ZM. Manifestations of chronic hepatitis C virus infection beyond the liver. Clin Gastroenterol Hepatol. 2010;12:1017–29.CrossRefGoogle Scholar
  13. 13.
    Rosen HR. Chronic hepatitis C infection. N Engl J Med. 2011;364:2429–38.PubMedCrossRefGoogle Scholar
  14. 14.
    Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Solá R, et al., ACCELERATE Investigators. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2007;357(2):124–34.Google Scholar
  15. 15.
    Diago M, Shiffman ML, Bronowicki JP, Zeuzem S, Rodriguez-Torres M, Pappas SC, et al. Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin. Hepatology. 2010;51(6):1897–903.PubMedCrossRefGoogle Scholar
  16. 16.
    Mecenate F, Pellicelli AM, Barbaro G, et al., Club Epatologi Ospedalieri (CLEO) Group. Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the CLEO trial. BMC Gastroenterol. 2010;10:21–7.Google Scholar
  17. 17.
    Swain MG, Lai MY, Shiffman ML, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology. 2010;139(5):1593–601.PubMedCrossRefGoogle Scholar
  18. 18.
    Morgan TR, Ghany MG, Kim HY, HALT-C Trial Group. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010;52(3):833–44.PubMedCrossRefGoogle Scholar
  19. 19.
    Poordad F, McCone J Jr, Bacon BR, et al., SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195–206.Google Scholar
  20. 20.
    Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405–16.PubMedCrossRefGoogle Scholar
  21. 21.
    Oze T, Hiramatsu T, Yakushijin T, et al. Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy (original research article). J Hepatol. 2011;54:604–11.PubMedCrossRefGoogle Scholar
  22. 22.
    Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399–401.PubMedCrossRefGoogle Scholar
  23. 23.
    Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010;139(1):120–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Sarrazin C, Susser S, Doehring A, et al. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol. 2011;54(3):415–21.PubMedCrossRefGoogle Scholar
  25. 25.
    Lin CL, Kao JH. The clinical implications of hepatitis B virus genotype: recent advances. J Gastroenterol Hepatol. 2011;26 Suppl 1:123–30.PubMedCrossRefGoogle Scholar
  26. 26.
    Gisbert JP, Chaparro M, Esteve M. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33(6):619–33.PubMedCrossRefGoogle Scholar
  27. 27.
    Lok ASF, McMahon BJ. AASLD practice guideline hepatitis B 2007. 2009 http://www.aasld.org/practiceguidelines/Pages/NewUpdatedGuidelines.aspx (free download).
  28. 28.
    Yuen MF, Lai CL. Treatment of chronic hepatitis B: evolution over two decades. J Gastroenterol Hepatol. 2011;26 Suppl 1:138–43.PubMedCrossRefGoogle Scholar
  29. 29.
    Liaw YF, Sheen IS, Lee CM, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology. 2011;53(1):62–72.PubMedCrossRefGoogle Scholar
  30. 30.
    Wedemeyer H, Yurdaydìn C, Dalekos GN, et al., HIDIT Study Group. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med. 2011;364(4):322–31.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Transplant DepartmentMethodist University HospitalMemphisUSA
  2. 2.Department of Internal MedicineUniversity of Tennessee Health Science CenterMemphisUSA

Personalised recommendations